无动物源, 无载体, His标签, ≥95%(SDS-PAGE), expressed in CHO; 见COA
生化机理
Bifikafusp alfa (Darleukin) is a fusion protein of pro-inflammatory IL-2 and an L19 human mAb fragment (scFv domain) that binds the tumour microenvironment expressed fibronectin extradomain B (EDB) [1]. Structurally it is a diabody with two IL-2 units per molecule. Incorporation of the L19 binding fragment targets the drug to the tumour, improving selective site accumulation and tumour killing and at the same time reducing the effective dose required to achieve a meaningful response, and reducing the otherwise dose-limiting toxicities associated with high-dose IL-2 administration that would be required to produce the same killing effect. Darleukin is one of a growing number of so-called 'immunocytokines' entering clinical development.
41.7 kDa, under reducing conditions; 40.8 kDa, under non-reducing conditions.
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存缓冲液
Lyophilized from PBS, pH 7.4
浓度
expressed in CHO; 见COA
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.5 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
-20℃保存 6个月；复溶后建议分装，避免反复冻融。
图片
Recombinant Human Bifikafusp alfa Protein (rp225852) - SDS-PAGE
3 μg/lane of Recombinant Human Bifikafusp alfa Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 41.7 kDa under reducing conditions and 40.8 kDa under non-reducing conditions.
危险品化学品经营许可证（带存储）